Invivyd Announces Continued Neutralizing Activity of PEMGARDA™ (pemivibart) Against Currently Dominant SARS-CoV-2 Variant LP.8.1
Portfolio Pulse from
Invivyd, Inc. announced that their product PEMGARDA™ (pemivibart) continues to show effective neutralizing activity against the dominant SARS-CoV-2 variant LP.8.1. This is significant for the company's position in COVID-19 treatments.
March 05, 2025 | 12:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Invivyd's PEMGARDA™ maintains its neutralizing activity against the dominant SARS-CoV-2 variant LP.8.1, which is positive for the company's COVID-19 treatment portfolio.
The announcement that PEMGARDA™ continues to neutralize the dominant COVID-19 variant LP.8.1 is likely to boost investor confidence in Invivyd's product efficacy and market position, potentially leading to a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100